Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression: A Double-Blind, Randomized Pilot Study in a Chinese Population
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
To compare the efficacy and tolerability of antidepressants switch with extended-release venlafaxine (venlafaxine-XR), mirtazapine, and paroxetine in Chinese patients with major depressive disorder who had 2 consecutive unsuccessful antidepressant trials. One hundred fifty adult patients with treatment-resistant depression according to their medical records and/or response to current treatments were randomly assigned to receive fixed-dosage treatment of venlafaxine-XR 225 mg/d (n = 50), mirtazapine 45 mg/d (n = 55), or paroxetine 20 mg/d (n = 45) for 8 weeks. The primary outcome was the remission rates that were defined as a score 7 or lower on the 17-item Hamilton Rating Scale for Depression (HRSD-17). Secondary outcomes included the remission rate defined by the Self-Rating Depression Scale of 50 or lower and the response rate defined by a 50% reduction or greater on the HRSD-17 total score, and the improvement of patients' general health functions. The completion rates were 82% for venlafaxine-XR, 81.8% for mirtazapine, and 82.2% for paroxetine. Only one patient in paroxetine arm discontinued the study owing to an adverse event. The remission rates based on the HRSD-17 were 42.0% for venlafaxine-XR, 36.4% for mirtazapine, and 46.7% for paroxetine. There were no statistical significances between treatment arms in remission rates. Similarly, there were also no significant differences between groups in secondary outcome measure. Venlafaxine-XR, mirtazapine, and paroxetine were equally effective in the treatment of Chinese patients with major depressive disorder who failed at least 2 previous antidepressant treatments. Selecting any of these 3 antidepressants as a third-step antidepressant is a reasonable choice for this group of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“Some of our patients were recruited based on their medical records and did not go through strict screening procedures for stage 2 TRD like the patients in the STAR*D study.(41) Therefore, some of the participants in our study might not have true stage 2 TRD.”
MethodSelf-citationBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 12×
“6%, respectively.(23) Meanwhile, Fava et al(24) found that in patients who failed an adequate dosage and duration of SSRI treatment, the response rate to mirtazapine treatment was 48%.”
BackgroundResultSelf-citationDEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Residual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470 · cited 1×
“Even among so-called responders, residual symptoms are common.(5) Patients who failed 2 or more antidepressants from different classes with adequate treatment durations and dosages are considered to have treatment-resistant depression (TRD).”
BackgroundSelf-citationValidity and Reliability of the Chinese Hamilton Depression Rating Scale
Zheng, Y., Zhao, J., Phillips, M., Liu, J., Cai, M., Sun, S., & Huang, M. (1988) · British Journal of Psychiatry · doi:10.1192/bjp.152.5.660 · Cited by 423
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308 · cited 2×
“New dual-action antidepressants, such as venlafaxine-XR and mirtazapine with different mechanisms on serotonin and norepinephrine systems, have been increasingly used in clinical practice because of their possible advantages, such as an earlier onset of action and higher remission rates relative to selective serotonin…”
BackgroundInfluentialLekman, M., Laje, G., Charney, D., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Lipsky, R., Wisniewski, S. R., Manji, H., McMahon, F. J., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.026 · Cited by 284
Entsuah, A. R., Huang, H., & Thase, M. E. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1106 · Cited by 245
Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomised comparison
Poirier, M.-F., & Boyer, P. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.1.12 · Cited by 185 · cited 11×
“A few studies have shown that paroxetine was associated with a poorer response than venlafaxine-XR for the treatment of patients with TRD.25,26 However, because of its acceptable efficacy and tolerability at a lower dosage, paroxetine is not only commonly used as a standard control antidepressant in many trials but al…”
BackgroundInfluentialMirtazapine Versus Venlafaxine in Hospitalized Severely Depressed Patients With Melancholic Features
Guelfi, J. D., Ansseau, M., Timmerman, L., & Kørsgaard, S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00010 · Cited by 138
Cited by
Sertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub4 · Cited by 299
Henssler, J., Alexander, D., Schwarzer, G., Bschor, T., & Baethge, C. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.4313 · Cited by 111
Papadimitropoulou, K., Vossen, C., Karabis, A., Donatti, C., & Kubitz, N. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1277201 · Cited by 91
Wu, Z., Chen, J., Yuan, C., Hong, W., Peng, D., Zhang, C., Cao, L., & Fang, Y. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.03.012 · Cited by 77
Li, Z., Zhang, Y., Wang, Z., Chen, J., Fan, J., Guan, Y., Zhang, C., Yuan, C., Hong, W., Wang, Y., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.10.003 · Cited by 63
Self-citation
Metadata
- Authors
- Fang, Y., Yuan, C., Xu, Y., Chen, J., Wu, Z., Cao, L., Yi, Z., Hong, W., Wang, Y., Jiang, K., Gao, K., Cui, X., & Nierenberg, A. A.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2010-08
- Volume
- 30
- Issue
- 4
- Pages
- 357-364
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2095071470
- Cited by
- 54
- References
- 10
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression: A Double-Blind, Randomized Pilot Study in a Chinese Population. https://app.cochat.ai/papers/10.1097/jcp.0b013e3181e7784f
- The paper
- Fang, Y., Yuan, C., Xu, Y., Chen, J., Wu, Z., Cao, L., Yi, Z., Hong, W., Wang, Y., Jiang, K., Gao, K., Cui, X., & Nierenberg, A. A. (2010). Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression: A Double-Blind, Randomized Pilot Study in a Chinese Population. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e3181e7784f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.